Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 153

Related Citations for PubMed (Select 25154027)

1.

Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies.

Smolewski P, Robak P, Cebula-Obrzut B, Misiewicz M, Mędra A, Majchrzak A, Witkowska M, Stromatt S, Robak T.

Eur J Cancer. 2014 Oct;50(15):2677-84. doi: 10.1016/j.ejca.2014.07.021. Epub 2014 Aug 18.

PMID:
25154027
2.

Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.

Rafiq S, Siadak A, Butchar JP, Cheney C, Lozanski G, Jacob NK, Lapalombella R, McGourty J, Moledor M, Lowe R, Setter B, Jones J, Flynn JM, Andritsos L, Devine S, Mo X, Jarjoura D, Tridandapani S, Algate P, Byrd JC, Muthusamy N.

MAbs. 2013 Sep-Oct;5(5):723-35. doi: 10.4161/mabs.25282. Epub 2013 Jun 7.

3.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
4.

Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells.

Yu B, Mao Y, Yuan Y, Yue C, Wang X, Mo X, Jarjoura D, Paulaitis ME, Lee RJ, Byrd JC, Lee LJ, Muthusamy N.

Biomaterials. 2013 Aug;34(26):6185-93. doi: 10.1016/j.biomaterials.2013.04.063. Epub 2013 May 28.

5.

A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies.

Deckert J, Park PU, Chicklas S, Yi Y, Li M, Lai KC, Mayo MF, Carrigan CN, Erickson HK, Pinkas J, Lutz RJ, Chittenden T, Lambert JM.

Blood. 2013 Nov 14;122(20):3500-10. doi: 10.1182/blood-2013-05-505685. Epub 2013 Sep 3.

6.
7.

The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model.

Beckwith KA, Frissora FW, Stefanovski MR, Towns WH, Cheney C, Mo X, Deckert J, Croce CM, Flynn JM, Andritsos LA, Jones JA, Maddocks KJ, Lozanski G, Byrd JC, Muthusamy N.

Leukemia. 2014 Jul;28(7):1501-10. doi: 10.1038/leu.2014.32. Epub 2014 Jan 21.

8.

rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia.

Ge X, Wu L, Hu W, Fernandes S, Wang C, Li X, Brown JR, Qin X.

Clin Cancer Res. 2011 Nov 1;17(21):6702-11. doi: 10.1158/1078-0432.CCR-11-0647. Epub 2011 Sep 14.

9.

Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.

Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ, Hoelzer D, Mitrou PS, Weidmann E.

Haematologica. 2002 Jan;87(1):33-43.

10.

A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies.

Heider KH, Kiefer K, Zenz T, Volden M, Stilgenbauer S, Ostermann E, Baum A, Lamche H, Küpcü Z, Jacobi A, Müller S, Hirt U, Adolf GR, Borges E.

Blood. 2011 Oct 13;118(15):4159-68. doi: 10.1182/blood-2011-04-351932. Epub 2011 Jul 27.

11.

Action of novel CD37 antibodies on chronic lymphocytic leukemia cells.

Krause G, Patz M, Isaeva P, Wigger M, Baki I, Vondey V, Kerwien S, Kuckertz M, Brinker R, Claasen J, Frenzel LP, Wendtner CM, Heider KH, Hallek M.

Leukemia. 2012 Mar;26(3):546-9. doi: 10.1038/leu.2011.233. Epub 2011 Sep 2. No abstract available.

PMID:
21886169
12.

Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical.

Zhao X, Lapalombella R, Joshi T, Cheney C, Gowda A, Hayden-Ledbetter MS, Baum PR, Lin TS, Jarjoura D, Lehman A, Kussewitt D, Lee RJ, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC.

Blood. 2007 Oct 1;110(7):2569-77. Epub 2007 Apr 17.

13.

Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.

Cardarelli PM, Quinn M, Buckman D, Fang Y, Colcher D, King DJ, Bebbington C, Yarranton G.

Cancer Immunol Immunother. 2002 Mar;51(1):15-24. Epub 2001 Dec 18.

PMID:
11845256
14.

TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies.

Robak T, Robak P, Smolewski P.

Curr Opin Investig Drugs. 2009 Dec;10(12):1383-90. Review.

PMID:
19943209
15.

Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.

Robak T.

Future Oncol. 2013 Jan;9(1):69-91. doi: 10.2217/fon.12.157. Review.

PMID:
23252565
16.

Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells.

Klitgaard JL, Koefoed K, Geisler C, Gadeberg OV, Frank DA, Petersen J, Jurlander J, Pedersen MW.

Br J Haematol. 2013 Oct;163(2):182-93. doi: 10.1111/bjh.12503. Epub 2013 Aug 8.

PMID:
23927424
17.

Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells.

Shan D, Ledbetter JA, Press OW.

Cancer Immunol Immunother. 2000 Mar;48(12):673-83.

PMID:
10752475
18.

The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.

Kabore AF, Sun J, Hu X, McCrea K, Johnston JB, Gibson SB.

Apoptosis. 2006 Jul;11(7):1175-93.

PMID:
16699949
19.

Anti-CD37 antibodies for chronic lymphocytic leukemia.

Robak T, Robak P.

Expert Opin Biol Ther. 2014 May;14(5):651-61. doi: 10.1517/14712598.2014.890182. Epub 2014 Feb 20. Review.

PMID:
24555705
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk